



GI Dynamics, Inc. - ASX Announcement

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2014

LEXINGTON, Massachusetts & SYDNEY, Australia – 28 October 2014 – GI Dynamics, Inc. (ASX: GID) will hold a conference call to discuss the company's financial results for the third quarter and six months ended **30 September 2014**, and its business outlook. Michael D. Dale, president and chief executive officer, will host the call with Robert Crane, chief financial officer.

The company will file its Appendix 4C with the ASX on Friday, 31 October 2014 (AEST). The briefing call to discuss financial results and business updates will be held at **5 p.m. U.S. EST on Tuesday, 4 November 2014 (9 a.m. AEST on Wednesday, 5 November 2014)**.

Accessing the Briefing Call via Webcast:

A live webcast of the call will be available on the GI Dynamics website at investor.gidynamics.com. The webcast can be directly accessed at: <http://edge.media-server.com/m/p/f7u6k33y/lan/en>

Accessing the Briefing Call via Telephone:

For those preferring to listen by telephone, please dial in five minutes prior to the start of the call and provide the **passcode 38279268**. Regional dial-in numbers are as follows:

- **United States** callers please dial toll-free **1 (888) 771-4371**
- **Australia** callers please dial toll-free **1 (800) 507-265**
- **International** callers please dial **1 (847) 585-4405**

Replay archive:

The webcast will be archived for 30 days following the call on the GI Dynamics website at investor.gidynamics.com.

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier[®], the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Investor Enquiries:

United States:
Robert Crane, Chief Financial Officer
+1 (781) 357-3250

Australia:
David Allen or John Granger, Hawkesbury Partners
Pty Limited
+61 2 9325 9046

Media Enquiries:

United States/Europe:
Dan Budwick, Pure Communications Inc.
+1 (973) 271-6085

Australia:
Angela Ceberano, Flourish PR
+61 3 9092 8445

www.gidynamics.com

US OFFICE & HEADQUARTERS: 25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301
EUROPEAN OFFICE: De Tweeling 20-22 's-Hertogenbosch 5215 MC, THE NETHERLANDS T: + 31 13 547 9300
AUSTRALIAN OFFICE: Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046
GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388